AR066348A1 - Inhibidores de las iap - Google Patents
Inhibidores de las iapInfo
- Publication number
- AR066348A1 AR066348A1 ARP080101812A ARP080101812A AR066348A1 AR 066348 A1 AR066348 A1 AR 066348A1 AR P080101812 A ARP080101812 A AR P080101812A AR P080101812 A ARP080101812 A AR P080101812A AR 066348 A1 AR066348 A1 AR 066348A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycle
- optionally substituted
- carbocycle
- halogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 24
- 125000000623 heterocyclic group Chemical group 0.000 abstract 18
- -1 thiono Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 125000002252 acyl group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91501007P | 2007-04-30 | 2007-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066348A1 true AR066348A1 (es) | 2009-08-12 |
Family
ID=39926122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101812A AR066348A1 (es) | 2007-04-30 | 2008-04-29 | Inhibidores de las iap |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8907092B2 (https=) |
| EP (1) | EP2148858A4 (https=) |
| JP (1) | JP5368428B2 (https=) |
| KR (1) | KR20100024923A (https=) |
| CN (1) | CN101687787A (https=) |
| AR (1) | AR066348A1 (https=) |
| AU (1) | AU2008245447C1 (https=) |
| BR (1) | BRPI0809867A2 (https=) |
| CA (1) | CA2683392A1 (https=) |
| CL (1) | CL2008001234A1 (https=) |
| IL (1) | IL201379A0 (https=) |
| MX (1) | MX2009011783A (https=) |
| NZ (2) | NZ598890A (https=) |
| PE (2) | PE20130150A1 (https=) |
| RU (1) | RU2491276C2 (https=) |
| TW (1) | TWI432212B (https=) |
| WO (1) | WO2008134679A1 (https=) |
| ZA (1) | ZA200906946B (https=) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| MX2007007195A (es) * | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
| US7772177B2 (en) | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| KR20090041391A (ko) | 2006-07-24 | 2009-04-28 | 테트랄로직 파마슈티칼스 | 이량체성 ｉａｐ 길항제 |
| CL2007002166A1 (es) | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
| ES2398791T3 (es) * | 2008-01-11 | 2013-03-21 | Genentech, Inc. | Inhibidores de IAP |
| JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用 |
| CN102171209A (zh) | 2008-08-02 | 2011-08-31 | 健泰科生物技术公司 | Iap抑制剂 |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US8415486B2 (en) | 2009-05-28 | 2013-04-09 | Tetralogic Pharmaceuticals Corp. | IAP inhibitors |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| KR20120118008A (ko) | 2009-12-18 | 2012-10-25 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제 |
| WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2013001660A (es) | 2010-08-11 | 2013-06-03 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TW201307309A (zh) | 2010-10-13 | 2013-02-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| NO2755614T3 (https=) | 2012-01-03 | 2018-03-31 | ||
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| US9353419B2 (en) | 2012-05-04 | 2016-05-31 | Novartis Ag | Biomarkers for IAP inhibitor therapy |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| NZ710929A (en) | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2015187998A2 (en) | 2014-06-04 | 2015-12-10 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| KR20170040249A (ko) | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TN2018000112A1 (en) | 2015-10-29 | 2019-10-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| IL290809B2 (en) | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| MX2019007646A (es) | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
| EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| US11485733B2 (en) | 2017-06-30 | 2022-11-01 | Bayer Animal Health Gmbh | Azaquinoline derivatives |
| CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
| WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| JP7607564B2 (ja) | 2018-12-21 | 2024-12-27 | ノバルティス アーゲー | Ｐｍｅｌ１７に対する抗体及びその結合体 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| CA3139337A1 (en) * | 2019-07-25 | 2021-01-28 | Lanzatech, Inc. | Secondary acetate fermentation |
| WO2021023698A1 (en) | 2019-08-02 | 2021-02-11 | Lanthiopep B.V | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| AR123492A1 (es) | 2020-09-14 | 2022-12-07 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3235132A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN119301125A (zh) | 2022-07-26 | 2025-01-10 | 诺华股份有限公司 | Akr1c3依赖性kars抑制剂的晶型 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| KR20250093324A (ko) * | 2022-09-29 | 2025-06-24 | 트랙트 파마슈티컬스, 인코포레이티드 | Iap 억제제로 유용한 화합물 및 조성물 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA1292840C (en) | 1985-09-26 | 1991-12-03 | David Harry Hawke | Sequencing of peptides |
| US4935494A (en) | 1988-11-15 | 1990-06-19 | City Of Hope | C-terminal peptide and protein sequencing |
| CA2012306A1 (en) | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| WO1992001938A1 (en) | 1990-07-20 | 1992-02-06 | City Of Hope | Derivatization of c-terminal proline |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| SK56798A3 (en) | 1995-10-30 | 1998-12-02 | Smithkline Beecham Corp | Protease inhibitors, pharmaceutical composition containing them and their use |
| AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6472172B1 (en) | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| CA2355215A1 (en) | 1998-12-28 | 2000-07-06 | Jim Wells | Identifying small organic molecule ligands for binding |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| EP1315811A2 (en) | 2000-08-24 | 2003-06-04 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
| US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| WO2003010184A2 (en) | 2001-02-08 | 2003-02-06 | Thomas Jefferson University | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis |
| AU2002253432B2 (en) | 2001-04-05 | 2005-03-24 | Torrent Pharmaceuticals Ltd. | Heterocyclic compounds for aging-related and diabetic vascular complications |
| CA2449168A1 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
| US20030157522A1 (en) | 2001-11-09 | 2003-08-21 | Alain Boudreault | Methods and reagents for peptide-BIR interaction screens |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| ATE415413T1 (de) | 2002-07-15 | 2008-12-15 | Univ Princeton | Iap-bindende verbindungen |
| WO2004017991A1 (en) | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
| JP4315249B2 (ja) | 2003-02-07 | 2009-08-19 | ジェネンテック・インコーポレーテッド | アポトーシス亢進のための組成物と方法 |
| US20040171554A1 (en) | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| IL156263A0 (en) | 2003-06-02 | 2004-01-04 | Hadasit Med Res Service | Livin-derived peptides, compositions and uses thereof |
| WO2005049853A2 (en) | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Compositions and methods for screening pro-apoptotic compounds |
| CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| US7932382B2 (en) | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| CN1926118A (zh) | 2004-03-01 | 2007-03-07 | 德克萨斯大学董事会 | 二聚的小分子细胞凋亡增强剂 |
| WO2005094818A1 (en) | 2004-03-23 | 2005-10-13 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| BRPI0511350A (pt) | 2004-07-02 | 2007-12-04 | Genentech Inc | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| MX2007007195A (es) * | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
| US7772177B2 (en) * | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| WO2007048224A1 (en) * | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| WO2007106192A2 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
| TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| BRPI0708942A2 (pt) | 2006-03-21 | 2011-06-14 | Joyant Pharmaceuticals Inc | composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica |
| WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044209B2 (en) | 2006-10-12 | 2011-10-25 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| US8063218B2 (en) | 2006-12-19 | 2011-11-22 | Genentech, Inc. | Imidazopyridine inhibitors of IAP |
| ES2398791T3 (es) | 2008-01-11 | 2013-03-21 | Genentech, Inc. | Inhibidores de IAP |
| CN102171209A (zh) | 2008-08-02 | 2011-08-31 | 健泰科生物技术公司 | Iap抑制剂 |
| JP2012500272A (ja) | 2008-08-16 | 2012-01-05 | ジェネンテック， インコーポレイテッド | Ｉａｐのアザインドールインヒビター |
-
2008
- 2008-04-29 PE PE2012001805A patent/PE20130150A1/es not_active Application Discontinuation
- 2008-04-29 NZ NZ598890A patent/NZ598890A/xx not_active IP Right Cessation
- 2008-04-29 CA CA002683392A patent/CA2683392A1/en not_active Abandoned
- 2008-04-29 PE PE2008000757A patent/PE20090211A1/es not_active Application Discontinuation
- 2008-04-29 RU RU2009144094/04A patent/RU2491276C2/ru not_active IP Right Cessation
- 2008-04-29 KR KR1020097024828A patent/KR20100024923A/ko not_active Abandoned
- 2008-04-29 BR BRPI0809867-0A patent/BRPI0809867A2/pt not_active IP Right Cessation
- 2008-04-29 EP EP08747109A patent/EP2148858A4/en not_active Withdrawn
- 2008-04-29 MX MX2009011783A patent/MX2009011783A/es not_active Application Discontinuation
- 2008-04-29 CN CN200880022901A patent/CN101687787A/zh active Pending
- 2008-04-29 AU AU2008245447A patent/AU2008245447C1/en not_active Ceased
- 2008-04-29 JP JP2010506573A patent/JP5368428B2/ja not_active Expired - Fee Related
- 2008-04-29 TW TW097115740A patent/TWI432212B/zh not_active IP Right Cessation
- 2008-04-29 CL CL200801234A patent/CL2008001234A1/es unknown
- 2008-04-29 US US12/598,027 patent/US8907092B2/en not_active Expired - Fee Related
- 2008-04-29 NZ NZ580226A patent/NZ580226A/xx not_active IP Right Cessation
- 2008-04-29 AR ARP080101812A patent/AR066348A1/es not_active Application Discontinuation
- 2008-04-29 WO PCT/US2008/061891 patent/WO2008134679A1/en not_active Ceased
-
2009
- 2009-10-06 ZA ZA2009/06946A patent/ZA200906946B/en unknown
- 2009-10-11 IL IL201379A patent/IL201379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200906946B (en) | 2011-05-25 |
| US8907092B2 (en) | 2014-12-09 |
| AU2008245447C1 (en) | 2014-11-20 |
| KR20100024923A (ko) | 2010-03-08 |
| NZ598890A (en) | 2013-10-25 |
| TW200902067A (en) | 2009-01-16 |
| BRPI0809867A2 (pt) | 2014-09-30 |
| PE20090211A1 (es) | 2009-04-02 |
| WO2008134679A1 (en) | 2008-11-06 |
| TWI432212B (zh) | 2014-04-01 |
| JP2010526079A (ja) | 2010-07-29 |
| AU2008245447A1 (en) | 2008-11-06 |
| RU2491276C2 (ru) | 2013-08-27 |
| US20110077265A1 (en) | 2011-03-31 |
| EP2148858A1 (en) | 2010-02-03 |
| JP5368428B2 (ja) | 2013-12-18 |
| CN101687787A (zh) | 2010-03-31 |
| CL2008001234A1 (es) | 2008-09-22 |
| IL201379A0 (en) | 2010-05-31 |
| NZ580226A (en) | 2012-11-30 |
| RU2009144094A (ru) | 2011-06-10 |
| CA2683392A1 (en) | 2008-11-06 |
| MX2009011783A (es) | 2009-12-04 |
| EP2148858A4 (en) | 2011-01-26 |
| AU2008245447B2 (en) | 2014-01-23 |
| PE20130150A1 (es) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066348A1 (es) | Inhibidores de las iap | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| PE20250157A1 (es) | Compuestos de modulacion de kras g12d | |
| CY1123308T1 (el) | Αναστολεας ινωσης | |
| MX2020000261A (es) | Nuevos compuestos. | |
| ES2606197T3 (es) | Moduladores pirrolidina de GPR40 | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR072488A1 (es) | Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas. | |
| CO6210724A2 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
| AR065815A1 (es) | Compuestos de dihidroindazol en el tratamiento de trastornos del hierro | |
| CY1117792T1 (el) | Ανταγωνιστες toy trpv4 | |
| MX2015005637A (es) | Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina. | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR087701A1 (es) | Derivados de pirazol con actividad inhibidora de sglt1 | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| AR069513A1 (es) | Derivados de amidas del acido 6,7-dihidro -5h-imidazo¿1,2-alfa]imidazol-3-carboxilico, y composiciones farmaceuticas que los contienen | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |